Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients. Several approved therapies have delivered strong responses for... CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients. Several approved therapies have delivered strong responses for patients with advanced blood cancers wher… [+3621 chars]
Source ↗Ticker
$JNJ
Unknown company
Recent Trump mentions
- News8/29/2026neutral
- News8/24/2026neutral
Pfizer vs. Johnson & Johnson: Which Pharma Giant Is Better Prepared for Its Patent Cliff? Patent expirations are forcing Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) to prove that their newer medicines can replace some of their most suc... Patent expirations are forcing Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) to prove that their newer medicines can replace some of their most successful franchises. Pfizer is simultan… [+5112 chars]
Source ↗ - News8/23/2026neutral
Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable? Healthcare investors looking for long-term growth don’t always have to choose between fast-growing companies and defensive businesses. Sometimes the more int... Healthcare investors looking for long-term growth don't always have to choose between fast-growing companies and defensive businesses. Sometimes the more interesting decision is between two high-qual… [+6023 chars]
Source ↗ - News8/13/2026neutral
Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief? The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. T... The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the… [+4425 chars]
Source ↗ - News8/10/2026neutral
Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings? Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts’ averag... Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts' average estimate of about $25.05 billion. Adj… [+7055 chars]
Source ↗ - News8/10/2026neutral
Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval? Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robo... Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization… [+7355 chars]
Source ↗ - News8/3/2026neutral
Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money’s July 23 episode. After days of urging... Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money's July 23 episode. After days of urging investors to accumulate the stock foll… [+5688 chars]
Source ↗ - News7/27/2026neutral
Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings? Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts’ averag... Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts' average estimate of about $25.05 billion. Adj… [+5326 chars]
Source ↗ - News7/27/2026mixed
President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump's financial disclosures released earlier this year. Now a top J&J executive is heading the other direction. The Insider Sale EVP of Global Corporate Affairs … Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump's financial disclosures released earlier this year. Now a top J&J executive is heading th… [+152 chars]
Source ↗ - News7/27/2026mixed
President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump’s financial disclosures released earlier this year. Now... Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump's financial disclosures released earlier this year. Now a top J&J executive is heading th… [+3561 chars]
Source ↗ - News7/5/2026neutral
Johnson & Johnson (JNJ) Is One Of Jim Cramer’s Top Performing 2026 Stocks We recently published Jim Cramer’s Biggest Winners to Buy: Top 20 AI & Other Stocks He Got Right in 2026. Johnson & Johnson (NYSE:JNJ) is one of the stocks d... We recently published Jim Cramer's Biggest Winners to Buy: Top 20 AI & Other Stocks He Got Right in 2026. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer. Healthcar… [+2184 chars]
Source ↗ - News6/14/2026neutral
Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained We recently published Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by... We recently published Jim Cramer Didnt Hold Back On SpaceXs IPO & Discussed These 12 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer. Johnson & Johnson… [+2240 chars]
Source ↗ - News6/5/2026neutral
Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations Johnson & Johnson (NYSE:JNJ) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer... Johnson & Johnson (NYSE:JNJ) was among Jim Cramers stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer highlighted the companys billion-dollar drugs… [+1781 chars]
Source ↗ - News5/22/2026neutral
Why Johnson & Johnson (JNJ) Still Fits a Defensive Growth Case Johnson & Johnson (NYSE:JNJ) is one of the best stocks to buy according to Goldman Sachs’ Conviction List. Goldman added Johnson & Johnson to its U.S. May... Johnson & Johnson (NYSE:JNJ) is one of the best stocks to buy according to Goldman Sachs Conviction List. Goldman added Johnson & Johnson to its U.S. May Directors Cut Conviction List on May … [+2045 chars]
Source ↗
Disclosed trades
No disclosed trades for $JNJ.